Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1369 Views
eMediNexus 03 July 2018
Findings of a new study presented June 24, 2018 at the 78th Scientific Sessions of the American Diabetes Association in Orlando, Florida show that addition of sotagliflozin 200/400 mg to optimized insulin therapy lowers HbA1c, body weight and the incidence of severe hypoglycemia after a year of treatment in patients with type 1 diabetes.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}